In patients with metastatic ccRCC, 12–14 weeks’ neoadjuvant pazopanib (VEGFR and PDGFR TKI) provided clinical benefit to 84% of patients, with a median 14% reduction in primary tumour size18. Here, PDGFRB is linked to nonpapillary renal cell carcinoma.